ARYx Therapeutics, Inc.
ARYX · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | -0.21 | 0.13 |
| FCF Yield | -30.29% | -25.02% | -25.16% | -6.92% |
| EV / EBITDA | -11.73 | -6.77 | -4.98 | -18.38 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.61 | 0.97 | 1.01 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -15.33% | 45.27% | -4.80% | 9.85% |
| Safety | ||||
| Net Debt / EBITDA | -4.83 | -2.11 | -0.55 | -0.87 |
| Interest Coverage | -5.72 | -8.33 | -13.87 | -10.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |